Skip to main content

COVID-19 Topic Center

Commentary

Commentary
In this week’s issue of Talking Therapeutics, Dr Jennings explores a new drug approval and what it means for patients with chronic kidney disease.
Commentary
“Goal-directed use of antihypertensives and statin drugs appear to be effective strategies to reduce atrial fibrillation incidence, morbidity, and mortality,” says Mark Munger, PharmD.
Commentary
In this week’s issue of Talking Therapeutics, Dr Jennings explores the science and promise of a recently approved novel medication for patients with HFrEF.
Commentary
Dr Jennings reviews evidence supporting colchicine use to further reduce residual disease burden in coronary artery disease but highlights why pharmacists need to keep several things in mind when dispensing colchicine to ensure that patients are kept safe.
Commentary
“Health care providers can be instrumental in recognizing and helping patients suffering with mental health issues by keeping the lines of communication open and providing patients with encouragement and support,” says Yvette C Terrie, BS Pharm, RPh, consultant pharmacist.
Commentary
When combining the high prevalence of hypertension with new aggressive treatment targets, a lot of patients may face the risk of having to take numerous drugs. In this week’s issue of Talking Therapeutics, Dr Jennings looks at a few recent and interesting articles surrounding this timely topic.
Commentary
In this week’s issue of Talking Therapeutics, Dr Jennings examine the latest study surrounding the murky subject of anticoagulating patients with severe COVID-19 infection, and what it means for frontline pharmacists practicing in the hospital setting.
Commentary
Ken Cahill, CEO and co-founder of SilverCloud Health, explains why the solution to improving mental health treatment should involve scaling preventative behavioral health services to a much broader population, and should involve a variety of stakeholders.
Commentary
Merissa Andersen, PharmD, MPH, International Medication Safety Management fellow, reviews premixed solutions given to pharmacies that are intended to reduce the potential for compounding errors and provide sterile products labeled with ingredients and a barcode but explains that errors associated…
Commentary
Dr Jennings reviews two of the latest trials evaluating the controversial topic of fish oils products, and attempts to get the bottom of this murky pond of conflicted evidence. 
Back to Top